Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best performing large cap stocks to buy. On September 29, Alnylam Pharmaceuticals announced new data analyses from the HELIOS-B Phase 3 study of its RNAi therapeutic, called AMVUTTRA (vutrisiran), presented at the Heart Failure Society of America/HFSA Annual Scientific Meeting 2025. The findings showed a reduction in gastrointestinal/GI events, which is a multisystem manifestation of transthyretin-mediated amyloidosis cardiomyopathy/ATTR-CM. Compare ...

Sep 28, 2025 11:13 AM Eastern Daylight Time Share New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran Treatment with Vutrisiran Led to 37- 49% Lower Rates of Gastrointestinal Events, a Multisystem Manifestation of ATTR-CM, Across Multiple Treatment Groups, Compared to Placebo – Additional Analyses Reinforce Vutrisiran's Safety and Efficacy Profile as a Monotherapy and Illustrate Consistent Benefit from Treatment with Vutrisiran ...